Lv75
4950 积分 2022-09-22 加入
OP0002 EFFICACY AND SAFETY OF EFGARTIGIMOD PH20 SC IN ADULT PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHY: PHASE 2 RESULTS FROM THE ALKIVIA STUDY
29天前
已完结
Upadacitinib Versus Tofacitinib in Anti‐ MDA5 ‐Positive Dermatomyositis With Interstitial Lung Disease: A Multi‐Centre Cohort Study Emulating a Target Trial
1个月前
已完结
Redefining Initial Rheumatoid Arthritis Treatment: Tofacitinib Outperforms Methotrexate in Disease Control – An Open-Label Randomised Controlled Trial
1个月前
已关闭
Infectious complications in lupus nephritis treatment: a systematic review and meta-analysis
1个月前
已完结
Glomerular Exostosin as a Subtype and Activity Marker of Class 5 Lupus Nephritis
1个月前
已完结
Systemic Lupus Erythematosus Women with Lupus Nephritis in Pregnancy Therapeutic Challenge (SWITCH): The Systemic Lupus International Collaborating Clinics experience
1个月前
已完结
Anti-C1q Antibody and Antiphospholipid Antibodies Jointly Predict Thrombosis in Membranous Lupus Nephritis: A Retrospective Cohort Study
1个月前
已关闭
Treatment nonresponders in lupus nephritis characteristically exhibit persistent type I interferon signalling in monocytes: a longitudinal single-cell transcriptomic analysis
1个月前
已完结
How good enough are the new therapies for lupus nephritis? A narrative review and a position paper
1个月前
已关闭
Phase IV safety evaluation of voclosporin in lupus nephritis patients using the FAERS database for a 42-month period (2021 – 2024)
1个月前
已关闭
皖公网安备34019202002308
